In the thesis, we developed and studied a novel polymer delivery system for the DNA-intercalator bearing radioisotope iodine-125. Auger electrons emitting radioisotopes (such as iodine-125 or indium-111) are a potentially effective cancer treatment. Their use as an effective cancer therapy requires that they will be transported within close proximity of DNA, where they induce double-strand breaks leading to the cell death. This type of therapy may be even more beneficial when associated with drug delivery systems. The DNA intercalators proved to be effective carriers for the delivery of Auger electron emitters into DNA. Therefore, the new radioiodinated DNA-intercalating ellipticinium derivatives were synthesized and characterized. These compounds were linked to N-(2-hydroxypropyl) methacrylamide copolymer with narrow molecular weight distribution via acid-sensitive hydrazone linker. The structure of the linker plays a crucial role in the biological effectivity of the delivery system, so it was optimized to be stable at pH 7.4 (representing the pH of blood plasma), whereas in slightly acidic pH in endosomes after the cell internalization, the radioiodine-containing biologically active intercalator is rapidly released from its polymer carrier. The intercalating ability of the active compound was...

M.Sc. (Chemistry) / Human immunodeficiency virus (HIV) is continuously rewriting medical history as one of the diseases affecting humankind. Current treatments available for HIV, namely antiretrovirals (ARVs), do not completely eradicate the virus from the body, leading to life time commitment. Many ARVs suffer from high toxicities and unpleasant side effects; as a result many patients do not adhere to the treatment. Nanoparticles (NPs) used as drug delivery systems (DDS) hold tremendous potential, since they can easily protect the drug from external environment and enter the human cells to deliver drugs. Therefore, the main objective of this work was to load two ARVs, namely lamivudine (LAM) and efavirenz (EFV), into a biodegradable, biocompatible poly(epsilon-caprolactone) (PCL) polymer based NPs. LAM is a hydrophilic drug suffering from low half life of 5 to 7 hours and many unpleasant side effects. EFV is a hydrophobic drug suffering from low aqueous solubility (4 μg/ml), which leads to a limited oral absorption and low bioavailability (40-45%).

M.Sc. (Pharmaceutical Affairs), Faculty of Health Sciences, University of the Witwatersrand, 2009

Resumo: A zidovudina (AZT) é o fármaco antiretroviral mais utilizado no tratamento da AIDS, porém possui baixa biodisponibilidade, pois sofre intenso metabolismo hepático. Para alcançar concentrações plasmáticas efetivas são requeridas doses altas e freqüentes, as quais podem chegar a níveis tóxicos. A via nasal tem sido proposta como uma rota alternativa para administração de fármacos que sofrem metabolismo pré-sistêmico, pois favorece a absorção direta para circulação sanguínea; porém, ela possui mecanismos de depuração mucociliar, os quais podem eliminar rapidamente a formulação da cavidade nasal. Sistemas de liberação mucoadesivos podem promover o contato prolongado entre a formulação e os sítios de absorção da cavidade nasal, retardando a depuração mucociliar. Alguns sistemas estabilizados por tensoativos, capazes de formar diferentes estruturas liotrópicas líquido cristalinas, têm sido propostos para aumentar o tempo de contato de formulações com as mucosas. Estes sistemas, ao entrar em contato com os fluidos aquosos que compõem o muco, se ordenam em cristais líquidos (CLs), formando uma matriz de liberação do fármaco. O objetivo deste trabalho foi desenvolver sistemas capazes de formar CLs, como potenciais sistemas mucoadesivos para administração intranasal do AZT. A caracterização por microscopia de luz polarizada e SAXS mostrou que microemulsões (MEs) formadas por AC205/ácido oléico/água formam CLs com a adição tanto de água como de fluído nasal simulado (FNS). As MEs foram capazes de incorporar cerca de 50 mg.g-1 de AZT. A mucoadesão foi avaliada por ensaios de reologia oscilatória, em que a adição de fase aquosa aumentou os módulos elásticos dos sistemas, e pela medida da força para remover as formulações a partir de um disco de mucina, obtidas através de um analisador de textura. Ensaios de liberação in vitro em... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Zidovudine (AZT) is the most widely used drug in AIDS treatment; however, AZT shows low oral bioavailability, since it suffers extensive hepatic metabolism. In order to maintain therapeutic levels, large doses have to be given frequently, which may reach toxic levels. The nasal route has been exploited as an alternative route of drugs that suffer first pass metabolism, as it ensures the direct drug absorption to blood circulation; however, the nasal route has mucociliary clearance mechanisms which can quickly remove the formulation of the nasal cavity. Mucoadhesive drug delivery systems can improve residence time of formulation in the nasal cavity absorption sites, delaying mucociliary clearance. Some surfactants systems which are able to form different liotropic liquid crystalline structures have been explored as a strategy to increase formulation residence time on the mucosa. When these systems are placed in physiologic aqueous environment, they can form a drug delivery matrix. The aim of this work was to develop systems capable of forming CLs as potential intranasal AZT mucoadhesive systems. The polarized light microscopy and SAXS characterization showed that microemulsions (MEs) composed by AC205/oleic acid/water form CLs with the addition of either water or simulated nasal fluid (FNS). The MEs were able to incorporate about 50 mg.g-1 of AZT. The mucoadhesion was evaluated both by oscillatory rheology, in which aqueous phase addition increased the elastic modulus of the systems, and by measurement of the necessary force to remove the formulations from mucin disc, obtained through texture analyzer. In vitro Franz' Cell drug release assay showed, according to the Weibull model, that phase transition sustained AZT release. These results suggest that the systems in hand have great potential for nasal AZT administration. / Orientador: Maria Palmira Daflon Gremião / Coorientador: Victor Hugo Vitorino Sarmento / Banca: Maria Palmira Daflon Gremião / Banca: Marcela Longhi / Banca: Rosângela Itri / Mestre

A doença de Chagas causada pelo Trypanosoma cruzi representa um grave problema de saúde pública na América Latina e cada vez mais em todo o mundo, afetando principalmente regiões de baixo poder aquisitivo, e por isso negligenciada pela indústria farmacêutica. Atualmente apenas um fármaco está disponível, o benzonidazol, o qual apresenta eficácia limitada e está associado a diversos efeitos colaterais. Estudos recentes demonstraram atividade tripanocida do ácido ursólico, entretanto sua utilização é limitada pela alta hidrofobicidade, sendo o uso dos nanocarreadores lipossomais reconhecido como uma estratégia promissora para solucionar tal limitação, além de serem sistemas altamente versáteis e biocompatíveis. Neste trabalho, foram desenvolvidos lipossomas de fosfatidilcolina e colesterol contendo ácido ursólico pela técnica da evaporação do solvente e hidratação do filme lipídico seguida de sonicação, permitindo a obtenção de vesículas unilamelares e com baixa polidispersividade. A partir da avaliação preliminar da estabilidade das dispersões, a adição do colesterol na razão molar 10:1 fosfatidilcolina:colesterol foi essencial para a manutenção do conteúdo encapsulado quando a formulação foi estocada em temperatura ambiente e melhor retenção do conteúdo a 4°C (90%). Após a liofilização o emprego de sucrose na razão molar 1:10 lipídeo:açúcar, a formulação manteve o tamanho e distribuição de tamanho e impediu a agregação das vesículas. A formulação obtida foi caracterizada por microscopia eletrônica de transmissão, apresentando diâmetro entre 100 e 120 nm, também observado pelo espalhamento dinâmico da luz. As análises por espectroscopia no infravermelho e calorimetria exploratória diferencial demonstraram uma forte interação do fármaco com a membrana fosfolipídica por interações de hidrogênio, assim como uma menor mobilidade das cadeias lipídicas e formação de uma matriz vítrea a qual foi responsável pela efetiva crioproteção das vesículas. Estudo in vitro do perfil de liberação do fármaco a partir dos lipossomas pela técnica da diálise resultou em alta retenção do conteúdo encapsulado e uma liberação sustentada deste. A partir de ensaio biológico in vitro empregando azul de trypan, a formulação liofilizada contendo ácido ursólico se mostrou segura até a concentração em que seria necessária para carrear 32 ?M do fármaco, considerando a linhagem de mamíferos LLC-MK2. Em relação à atividade tripanocida em linhagem da cepa CL da forma epimastigota empregando MTT, o lipossoma contendo o fármaco foi capaz de causar morte celular do parasita em 100%, considerando-se um possível efeito sinérgico do ácido ursólico e o colesterol, cuja seletividade à membrana do parasita tem sido recentemente demonstrada. Contudo apenas a formulação contendo o ácido ursólico apresentou índice de seletividade aceitável, o que está relacionado com o efeito citoprotetor do ácido ursólico. / Chagas disease caused by Trypanosoma cruzi is a serious public health problem in Latin America and is an increasing disease around the world, mainly affecting regions with low purchasing power, and therefore Chagas disease is considered neglected by the pharmaceutical industry. Today, only one product is available, benznidazole, which has limited efficacy and is associated with several side effects. Recent studies have shown trypanocidal activity of ursolic acid, however its use is limited by the high hydrophobicity. The use of liposomal nanocarriers is recognized as a promising strategy to address this limitation and they are highly versatile and biocompatible systems. In this study, ursolic acid loaded phosphatidylcholine and cholesterol liposomes were developed using the solvent evaporation and lipid film hydration technique followed by sonication, allowing unilamellar vesicles formation with low polydispersity. From the preliminary assessment of the dispersion stability, the addition of cholesterol allowed the encapsulation efficiency maintenance when the formulation was stored at room temperature and better drug retention at 4°C (90%). After lyophilization employing sucrose 1:10 lipid:sugar molar ratio, the formulation manteined the size and size distribution and vesicle aggregation was prevented. The formulation obtained was characterized by transmission electron microscopy, with diameter between 100 and 120 nm, also observed by dynamic light scattering. The analysis by infrared spectroscopy and differential scanning calorimetry showed a strong hydrogen interaction between ursolic acid and the phospholipid membrane, as well as a lower mobility of the lipid chains and glassy matrix formation which was responsible for the effective cryoprotection. In vitro drug release profile from liposomes by dialysis technique resulted in high retention of the encapsulated content and a sustained release. From in vitro biological assay using trypan blue, the ursolic acid loaded lyophilized liposomes proved to be safe up to a concentration that would be required to carry 32 ?M of the drug, considering the LLC-MK2 mammalians cell line. Regarding the trypanocidal activity of epimastigotes CL strain by MTT technique, the ursolic acid loaded liposomes showed greater efficacy than blank liposome able to causing 100% of parasite cell death, considering a possible synergism effect of ursolic acid and cholesterol, whose selectivity to the parasite membrane has been recently demonstrated. However, only the formulation containing ursolic acid showed acceptable selectivity index, which is related to the ursolic acid cytoprotective effect.

The blood-brain barrier (BBB) is physiologically essential for brain homeostasis. While it protects the brain from noxious agents, it prevents almost all currently available drugs from crossing to the parenchyma. This greatly hinders drug delivery for the treatment of neurological diseases and disorders such as Parkinson’s, Alzheimer’s and Huntington’s, as well as the development of drugs for the treatment of such diseases. Current drug delivery techniques to the brain are either invasive and target specific, or non-invasive with low special specificity. Neither group of techniques are optimal for long term treatment of patients with neurological diseases or disorders. Focused ultrasound coupled with intravenous administration of microbubbles (FUS) has been proven as an effective technique to selectively and noninvasively open the BBB in multiple in vivo models including non-human primates (NHP). Although this technique has promising potential for clinical outpatient procedures, as well as a powerful tool in the lab, the safety and potential neurological effects of this technique need to be further investigated. This thesis focuses on validating the safety and efficacy of using the FUS technique to open the BBB in NHP as well as the ability of the technique to facility drug delivery. First, a longitudinal study of repeatedly applying the FUS technique targeting the basal ganglia region in four NHP was conducted to determine any potential long-term adverse side effects over a duration of 4-20 months. The safety of the technique was evaluated using both MRI as well as behavioral testing. Results demonstrated that repeated application of the FUS technique to the basal ganglia in NHP did not generate permanent side effects, nor did it induce a permanent opening of the BBB in the targeted region. The second study investigated the potential of the FUS technique as a method to deliver drugs, such as a low dose of haloperidol, to the basal ganglia in NHP and mice to elicit pharmacodynamical effects on responses to behavioral tasks. After opening the BBB in the basal ganglia of mice and NHP, a low dose of haloperidol was successfully delivered generating significant changes in their baseline motor responses to behavioral tasks. Domperidone was also successfully delivered to the caudate of NHP after opening the BBB and induced transient hemilateral neglect. In the final section of this thesis, the safety and efficacy of the FUS technique was evaluated in fully alert NHP. The FUS technique was successful in generating BBB opening volumes larger on average to that of the BBB opening volumes in anesthetized experiments. Safety results through MRI verification as well as behavioral testing during application of the technique demonstrated that the FUS technique did not generate adverse neurological effects. Conversely, the FUS technique was found to induce slight positive effects on the response of the NHP to the behavioral task. Collectively, the work presented in this thesis demonstrates the safety and effectiveness of the FUS technique to open the BBB and deliver neuroactive drugs in the NHP.

Glioblastoma is the most common adult malignant primary brain tumor with one of the worst prognosis. With a survival of 10 to 12 months, glioblastoma remains one of the most challenging disease to treat. The standard treatment method involves maximal possible resection of the tumor followed by radiation and chemotherapy. However, the short half-life of most chemotherapeutic drugs, high systemic toxicity and inability to cross the blood brain barrier inhibits effective delivery of the chemotherapeutics to the tumor. An ideal drug delivery system can reach the tumor site with high efficiency and continuously release the drug at the tumor site for an extended period. Adult stem cells including neural stem cells (NSC) and mesenchymal stem cells (MSC) have inherent tumor trophic properties allowing for site-specific delivery of chemotherapeutics. They can also be genetically engineered to secrete the chemotherapeutic drug continuously making them ideal candidates for cell-based delivery system for treating glioblastoma. MSC have been isolated from a wide range of sources including bone marrow, umbilical cord, adipose tissue, liver, multiple dental tissues and induced pluripotent stem cells. MSC are also easily amenable to viral modification allowing for easy manipulation to produce chemotherapeutic drugs. Additionally, more than 350 clinical trials using MSC have successfully established the safety of using MSC for cell-based therapies. Collectively these factors have led to the widespread use of MSC in cancer therapy. MSC have been successfully transduced to produce chemotherapeutic drugs to treat glioma, melanoma, lung cancer, ovarian cancer and breast cancer. Despite the multitudes of advantages that cell therapy provides they are limited in three main domains (1) Low cell retention and survival at the site of the tumor (2) In ability to co-deliver multiple therapeutics and (3) In ability to deliver drugs other than peptide based drugs. This thesis details the work to engineer mesenchymal stem cells to tackle these three issues and develop a system that can increase the efficacy of glioblastoma treatment. To increase the cellular retention and survival we engineered MSC to form multicellular spheroids and cell sheets. To co-delivery multiple therapeutics we engineered MSC to form MSC/DNA-templated nanoparticle hybrid cluster to co-deliver drugs for cancer therapy. The system showed superior performance due to the increased retention of the cells and nanoparticle at the tumor site. Finally, to deliver drugs other peptide based we engineered graphene oxide cellular patches for mesenchymal stem cells. Graphene oxide can carry diverse therapeutics and can kill the cancer cells without affecting the cellular viability of MSC.

No description available.

The potential of magnetic nanoparticle-vesicle assemblies (MNP-V) as remote controlled drug delivery platforms capable of inducing cellular responses under magnetic stimuli has been previously demonstrated in the Webb group at the University of Manchester. To create these magnetoresponsive nanomaterials biotin-avidin and Cu-histidinyl multivalent recognition were employed. This thesis describes an exploration of the potential of thiol-thioester exchange reactions (leading to native chemical ligation, NCL) to create magnetoresponsive materials, which potentially have applications in biomedicine. Firstly, iron oxide magnetic nanoparticles have been synthesised using a thermal co-precipitation method followed by chemical modification with sulfhydryl motifs for use as smart biomaterials. Knowing that the behaviour and reactivity of nanoparticles is highly influenced by their physicochemical properties, a thourough characterisation of these particles has been obtained. Secondly, during this project, several thioester derivatives have been synthesised that can be incorporated into the membranes of 800 nm liposomes. Among these, the spectrophotometric properties of synthetic lipid 38 allowed the investigation of trans-thioesterification rates with cysteinyl functionalities, both in solution and at the phospholipid membrane interface of liposomes. Product identification has been achieved using mass spectrometry and 1H-NMR spectroscopy. Finally, the conditions required to induce the release of a dye (e.g. 5(6)-CF) from MNP-V upon exposure to an AMF pulse have been established. Aurintricarboxylic acid (ATA), a general inhibitor of nucleases has been investigated as interesting payload due to its fluorescent and anti-viral properties.

Ng, Yiu Ming. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2011. / Includes bibliographical references (leaves 99-114). / Abstracts in English and Chinese. / Acknowledgements --- p.2 / Abstract --- p.3 / 摘要 --- p.5 / Content --- p.6 / List of abbreviations and symbols --- p.10 / Chapter Chapter 1 - --- Introduction --- p.13 / Chapter 1.1 --- Introduction to nanoparticles (NPs) --- p.13 / Chapter 1.2 --- How to treat solid cancers using nanoparticle drugs --- p.17 / Chapter 1.3 --- What is Chitosan (CS)? --- p.22 / Chapter 1.4 --- Possible peptide candidates to be trapped --- p.26 / Chapter 1.4.1 --- Luffin PI - Ribosome inactivating peptide --- p.26 / Chapter 1.4.2 --- Buforin lib (Bllb) - Antimicrobial peptide --- p.27 / Chapter 1.5 --- Aims of study --- p.30 / Chapter Chapter 2 - --- Materials and Methods --- p.31 / Chapter 2.1 --- Materials --- p.31 / Chapter 2.2 --- Methods --- p.31 / Chapter 2.2.1 --- Construction and expression of Luffin P1 --- p.31 / Chapter 2.2.2 --- Circular dichroism spectroscopy --- p.32 / Chapter 2.2.3 --- Static light scattering --- p.33 / Chapter 2.2.4 --- In vitro N-glycosidase assay --- p.34 / Chapter 2.2.5 --- Preparation of CS particles --- p.34 / Chapter 2.2.5.1 --- Preparation of positive CS NPs --- p.34 / Chapter 2.2.5.2 --- Preparation of negative CS NPs --- p.35 / Chapter 2.2.5.3 --- Preparation of buforin lib incorporated NPs --- p.35 / Chapter 2.2.5.4 --- Preparation of Cy5 incorporated NPs --- p.36 / Chapter 2.2.6 --- Characterization of CS NPs --- p.36 / Chapter 2.2.7 --- Buforin lib (Bllb) encapsulation efficiency and loading capacity --- p.36 / Chapter 2.2.8 --- In vitro release study --- p.37 / Chapter 2.2.9 --- Confocal Microscopy --- p.37 / Chapter 2.2.10 --- Cytotoxicity assay --- p.38 / Chapter 2.2.11 --- Statistical analysis --- p.38 / Chapter Chapter 3 - --- "Cloning, expression, purification and structural characterization of Luffin PI" --- p.39 / Chapter 3.1 --- Introduction --- p.39 / Chapter 3.2 --- Results --- p.41 / Chapter 3.2.1 --- Construction of Luffin PI plasmid --- p.41 / Chapter 3.2.2 --- Expression and purification of Luffin PI --- p.41 / Chapter 3.3.3 --- Molecular weight and secondary structure determination of Luffin PI --- p.43 / Chapter 3.3.4 --- 3D solution structure of Luffin PI --- p.45 / Chapter 3.3.5 --- In vitro N-glycosidase activity of Luffin PI --- p.49 / Chapter 3.3 --- Discussion --- p.51 / Chapter Chapter 4 - --- Generation of positively charged CS particles and Bllb incorporation --- p.60 / Chapter 4.1 --- Introduction --- p.60 / Chapter 4.2 --- Results --- p.62 / Chapter 4.2.1 --- Positively charged CS NPs generation --- p.62 / Chapter 4.2.2 --- Bllb incorporated +ve CS NPs generation --- p.68 / Chapter 4.2.3 --- In vitro release study --- p.70 / Chapter 4.2.4 --- In vitro cytotoxicity test --- p.72 / Chapter 4.3 --- Discussion --- p.74 / Chapter Chapter 5 - --- Generation of negatively charged CS particles and Bllb incorporation --- p.83 / Chapter 5.1 --- Introduction --- p.83 / Chapter 5.2 --- Results --- p.85 / Chapter 5.2.1 --- -ve CS NPs generation --- p.85 / Chapter 5.2.2 --- -ve CS-Bllb NPs generation --- p.88 / Chapter 5.2.3 --- In vitro release study --- p.91 / Chapter 5.2.4 --- Localization study of -ve CS-Bllb NPs --- p.93 / Chapter 5.2.5 --- In vitro cytotoxicity test --- p.96 / Chapter 5.3 --- Discussion --- p.98 / Chapter Chapter 6 - --- Conclusion and future work --- p.108 / Copyright --- p.110 / References --- p.111